Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilar User Fees Could Be Raised Significantly In Renewal Talks

Executive Summary

Workload is not what was expected when BsUFA was designed, FDA says.

You may also be interested in...



Biosimilar User Fees Discounted To Begin Second Round

After adjusting for expected workload, US FDA reduces biosimilar user fee revenue target, which lowered application fees.

Biosimilar User Fees Discounted To Begin Second Round

After adjusting for expected workload, US FDA reduces biosimilar user fee revenue target, which lowered application fees.

Biosimilar Suffix Detractors Hope Private Studies Build Their Case

Consortium’s biosimilar pharmacovigilance could provide data foundation to pressure FDA that suffixes are not needed in non-proprietary names.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS057238

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel